A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation

• Participants must be 18 years old or older, with no gender restrictions;
• First-time allogeneic hematopoietic stem cell transplantation patients;
• Platelet count between 20×10*9/L ;
• Absence of peripheral blood platelet transfusions in the three days prior to receiving human-induced pluripotent stem cell-derived platelets;
• ECOG score of ≤ 2;
• Participants and/or their guardians (if applicable) must comprehend and sign the informed consent form.

Exclusion Criteria:

• History of ineffective platelet transfusion ;
• Platelet antibody positive, and/or donor-specific antibody (DSA) positive ；
• Individuals with severe transfusion related allergic reactions in the past; Patients with recurrent malignant hematological tumors that have not yet improved;
• Within 7 days prior to receiving the investigational drug;
• Patients with existing severe bleeding (such as intracranial hemorrhage, severe gastrointestinal bleeding, or severe hemoptysis);
• For patients with hemophilia and coagulation system diseases;
• History of pulmonary embolism and hepatic vein thrombosis;
• Patients with disseminated intravascular coagulation;
• Use of anticoagulant medications within 7 days before screening;
• Individuals with positive results in screening for antibodies against the human immunodeficiency virus or specific antibodies against Treponema pallidum (the causative agent of syphilis); or those who test positive for hepatitis C antibodies, hepatitis B surface antigen, or have a history of hepatitis B, or individuals with positive hepatitis B core antibodies and HBV-DNA ≥2000 IU/mL in the past 3 months;
• Individuals with uncontrolled active infections;
• Body weight exceeding 80 kg;
• Have undergone hematopoietic stem cell transplantation and have an acute graft-versus-host disease that requires control;
• Women of childbearing age who are pregnant or breastfeeding, and male participants who plan to donate sperm within 180 days after medication administration;
• The investigator believes that due to any medical condition, the assessment cannot be part of this study, or the participant is unable to complete the follow-up investigation.